(NMRA) Neumora Therapeutics - Ratings and Ratios
Depression, Schizophrenia, Anxiety, Addiction
Description: NMRA Neumora Therapeutics
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The companys pipeline includes several promising candidates, with navacaprant (NMRA-140) being the most advanced, currently in Phase 3 clinical trials for major depressive disorder.
The companys diverse portfolio also includes NMRA-511 in Phase 1 clinical trials for agitation associated with dementia due to Alzheimers disease, as well as several preclinical programs targeting conditions such as schizophrenia, amyotrophic lateral sclerosis, and Parkinsons disease. With a strong focus on neuroscience, Neumora Therapeutics is poised to address significant unmet medical needs in the field.
From a trading perspective, key performance indicators (KPIs) such as trading volume, short interest, and institutional ownership can provide valuable insights. As a Trading Analyst, I would monitor these metrics to gauge market sentiment and potential price movements. For instance, a significant increase in trading volume could indicate growing interest in the stock, while a high short interest ratio might suggest a potential short squeeze.
In terms of valuation, Neumora Therapeutics market capitalization of $208.65M USD and lack of earnings (P/E: None) suggest that investors are currently pricing in future growth potential rather than current profitability. To evaluate the companys prospects, I would analyze KPIs such as R&D expenses as a percentage of market capitalization, pipeline progress, and upcoming milestones, which can help estimate the potential return on investment.
To make informed investment decisions, it is essential to stay up-to-date on Neumora Therapeutics clinical trial results, regulatory updates, and industry trends. By closely monitoring these factors and applying a data-driven approach, investors can better navigate the complexities of the biopharmaceutical industry and capitalize on emerging opportunities.
NMRA Stock Overview
| Market Cap in USD | 282m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2023-09-14 |
NMRA Stock Ratings
| Growth Rating | -85.9% |
| Fundamental | 24.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -89.6% |
| Analyst Rating | 3.50 of 5 |
NMRA Dividends
Currently no dividends paidNMRA Growth Ratios
| Growth Correlation 3m | 50.1% |
| Growth Correlation 12m | -69.9% |
| Growth Correlation 5y | -76.3% |
| CAGR 5y | -70.87% |
| CAGR/Max DD 3y | -0.73 |
| CAGR/Mean DD 3y | -1.51 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | 0.10 |
| Beta | 0.835 |
| Volatility | 76.02% |
| Current Volume | 552.6k |
| Average Volume 20d | 339.4k |
| Stop Loss | 1.3 (-10.3%) |
| Signal | -0.95 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-252.1m TTM) > 0 and > 6% of Revenue (6% = -15.1m TTM) |
| FCFTA -0.82 (>2.0%) and ΔFCFTA -41.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.87 (>3.0%) and CFO -195.7m > Net Income -252.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.7m) change vs 12m ago 1.70% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover -80.14% (prev 0.0%; Δ -80.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -41.53
| (A) 0.90 = (Total Current Assets 222.9m - Total Current Liabilities 21.2m) / Total Assets 223.8m |
| (B) -4.77 = Retained Earnings (Balance) -1.07b / Total Assets 223.8m |
| warn (B) unusual magnitude: -4.77 — check mapping/units |
| (C) -0.67 = EBIT TTM -210.7m / Avg Total Assets 314.1m |
| (D) -26.08 = Book Value of Equity -1.07b / Total Liabilities 40.9m |
| Total Rating: -41.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.54
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin -72.66% = -7.50 |
| 4. Debt/Equity 0.11 = 2.49 |
| 5. Debt/Ebitda -0.09 = -2.50 |
| 6. ROIC - WACC (= -89.64)% = -12.50 |
| 7. RoE -98.95% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend 40.95% = 2.05 |
What is the price of NMRA shares?
Over the past week, the price has changed by -11.04%, over one month by -11.59%, over three months by +82.85% and over the past year by -87.64%.
Is Neumora Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NMRA is around 1.28 USD . This means that NMRA is currently overvalued and has a potential downside of -11.72%.
Is NMRA a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NMRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.1 | 317.2% |
| Analysts Target Price | 6.1 | 317.2% |
| ValueRay Target Price | 1.4 | -2.1% |
Last update: 2025-09-04 04:44
NMRA Fundamental Data Overview
CCE Cash And Equivalents = 217.6m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -252.1m + Cost of Revenue 318.0k = -251.8m USD
P/B = 1.5408
Beta = None
Revenue TTM = -251.8m USD
EBIT TTM = -210.7m USD
EBITDA TTM = -210.2m USD
Long Term Debt = 19.5m USD (from longTermDebt, last quarter)
Short Term Debt = 171.0k USD (from shortTermDebt, last quarter)
Debt = 19.6m USD (Calculated: Short Term 171.0k + Long Term 19.5m)
Net Debt = -124.0m USD (from netDebt column, last quarter)
Enterprise Value = 83.8m USD (281.8m + Debt 19.6m - CCE 217.6m)
Interest Coverage Ratio = unknown (Ebit TTM -210.7m / Interest Expense TTM 0.0)
FCF Yield = -218.3% (FCF TTM -182.9m / Enterprise Value 83.8m)
FCF Margin = -72.66% (FCF TTM -182.9m / Revenue TTM -251.8m)
Net Margin = -100.1% (Net Income TTM -252.1m / Revenue TTM -251.8m)
Gross Margin = -100.1% ((Revenue TTM -251.8m - Cost of Revenue TTM 318.0k) / Revenue TTM)
Tobins Q-Ratio = -0.08 (set to none) (Enterprise Value 83.8m / Book Value Of Equity -1.07b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 19.6m)
Taxrate = 21.0% (US default)
NOPAT = -210.7m (EBIT -210.7m, no tax applied on loss)
Current Ratio = 10.54 (Total Current Assets 222.9m / Total Current Liabilities 21.2m)
Debt / Equity = 0.11 (Debt 19.6m / last Quarter total Stockholder Equity 182.9m)
Debt / EBITDA = -0.09 (Net Debt -124.0m / EBITDA -210.2m)
Debt / FCF = -0.11 (Debt 19.6m / FCF TTM -182.9m)
Total Stockholder Equity = 254.8m (last 4 quarters mean)
RoA = -112.6% (set to none)
RoE = -98.95% (Net Income TTM -252.1m / Total Stockholder Equity 254.8m)
RoCE = -76.82% (Ebit -210.7m / (Equity 254.8m + L.T.Debt 19.5m))
RoIC = -81.14% (NOPAT -210.7m / Invested Capital 259.6m)
WACC = 8.50% (E(281.8m)/V(301.4m) * Re(9.09%)) + (D(19.6m)/V(301.4m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 88.40 | Cagr: 0.57%
Discount Rate = 9.09% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -182.9m)
EPS Correlation: 40.95 | EPS CAGR: -2.92% | SUE: 0.34 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for NMRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle